Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Recognizing rare disorders: aromatase deficiency

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 414–421 (2007)Cite this article

Abstract

Aromatase deficiency is rare in humans. Affected individuals cannot synthesize endogenous estrogens. Aromatase is the enzyme that catalyzes conversion of androgens into estrogens, and if aromatase is nonfunctional because of an inactivating mutation, estrogen synthesis cannot occur. If the fetus lacks aromatase activity, dehydroepiandrosterone sulfate produced by the fetal adrenal glands cannot be converted to estrogen by the placenta, so is converted to testosterone peripherally and results in virilization of both fetus and mother. Virilization manifests as pseudohermaphroditism in female infants, with hirsutism and acne in the mother; the maternal indicators resolve following delivery. To date, only seven males and seven females with aromatase deficiency have been reported. Affected females are typically diagnosed at birth because of the pseudohermaphroditism. Cystic ovaries and delayed bone maturation can occur during childhood and adolescence in these girls, who present at puberty with primary amenorrhea, failure of breast development, virilization, and hypergonadotrophic hypogonadism. Affected males, on the other hand, do not present with obvious defects at birth, so are diagnosed much later in life, presenting with clinical symptoms, which include tall stature, delayed skeletal maturation, delayed epiphyseal closure, bone pain, eunuchoid body proportions and excess adiposity. Estrogen replacement therapy reverses the symptoms in male and female patients.

Key Points

  • Aromatase deficiency is rare

  • Aromatase deficiency should be suspected in any pregnancy in which the mother becomes virilized

  • This condition should be suspected when a female newborn presents with ambiguous genitalia

  • When an adult male presents with tall stature, delayed skeletal maturation, delayed epiphyseal closure, eunuchoid body proportions, and undetectable estrogens concomitant with elevated levels of testosterone, aromatase deficiency should be suspected

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Photograph of aromatase-deficient man,11 demonstrating genu valgum

Similar content being viewed by others

References

  1. Simpson ER et al. (1997) Aromatase expression in health and disease. Recent Prog Horm Res 52: 185–213

    CAS  PubMed  Google Scholar 

  2. Simpson ER et al. (1987) Sequencing of cDNA inserts encoding aromatase cytochrome P-450 (P-450AROM). Mol Cell Endocrinol 52: 267–272

    Article  CAS  Google Scholar 

  3. Bulun SE (2004) et al. Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 22: 5–9

    Article  CAS  Google Scholar 

  4. Simpson E et al. (2000) The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab 11: 184–188

    Article  CAS  Google Scholar 

  5. Mahendroo MS et al. (1993) Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 268: 19463–19470

    CAS  PubMed  Google Scholar 

  6. Jones ME et al. (2006) Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 17: 55–64

    Article  Google Scholar 

  7. Bouillon R et al. (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89: 6025–6029

    Article  CAS  Google Scholar 

  8. Carani C et al. (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337: 91–95

    Article  CAS  Google Scholar 

  9. Deladoey J et al. (1999) Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 84: 4050–4054

    CAS  PubMed  Google Scholar 

  10. Herrmann BL et al. (2002) Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 87: 5476–5484

    Article  CAS  Google Scholar 

  11. Maffei L et al. (2004) Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89: 61–70

    Article  CAS  Google Scholar 

  12. Morishima A et al. (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689–3698

    CAS  PubMed  Google Scholar 

  13. Pura MM et al. (2003) Clinical findings in an adult man with a novel mutation in the aromatase gene [abstract]. In The 85th Annual Meeting of The Endocrine Society: 2003 June 19–22; Philadelphia, 1–467

    Google Scholar 

  14. Belgorosky A et al. (2003) Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metab 88: 5127–5131

    Article  CAS  Google Scholar 

  15. Conte FA et al. (1994) A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 78: 1287–1292

    CAS  PubMed  Google Scholar 

  16. Ludwig M et al. (1998) Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene. J Pediatr Endocrinol Metab 11: 657–664

    Article  CAS  Google Scholar 

  17. Mullis PE et al. (1997) Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 82: 1739–1745

    CAS  PubMed  Google Scholar 

  18. Portrat-Doyen S et al. (1996) Female pseudohermaphroditism (FPH) resulting from aromatase (P450arom) deficiency associated with a novel mutation (R457X) in the CYP19 gene [abstract]. Horm Res 46 (Suppl 2): S14

    Google Scholar 

  19. Shozu M et al. (1991) A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 72: 560–566

    Article  CAS  Google Scholar 

  20. Chen S and Zhou D (1992) Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. J Biol Chem 267: 22587–22594

    CAS  PubMed  Google Scholar 

  21. Bulun SE (1996) Clinical review 78: aromatase deficiency in women and men: would you have predicted the phenotypes? J Clin Endocrinol Metab 81: 867–871

    Article  CAS  Google Scholar 

  22. Simpson ER (2004) Models of aromatase insufficiency. Semin Reprod Med 22: 25–30

    Article  CAS  Google Scholar 

  23. Smith EP et al. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056–1061

    Article  CAS  Google Scholar 

  24. Oettel M (2002) Is there a role for estrogens in the maintenance of men's health? Aging Male 5: 248–257

    Article  CAS  Google Scholar 

  25. Gennari L et al. (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89: 5898–5907

    Article  CAS  Google Scholar 

  26. Khosla S et al. (2002) Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 87: 1443–1450

    Article  CAS  Google Scholar 

  27. Bilezikian JP et al. (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339: 599–603

    Article  CAS  Google Scholar 

  28. Herrmann BL et al. (2005) Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency. Horm Metab Res 37: 178–183

    Article  CAS  Google Scholar 

  29. Riggs BL et al. (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279–302

    Article  CAS  Google Scholar 

  30. Rochira V et al. (2002) Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol 193: 19–28

    Article  CAS  Google Scholar 

  31. Faustini-Fustini M et al. (1999) Oestrogen deficiency in men: where are we today? Eur J Endocrinol 140: 111–129

    Article  CAS  Google Scholar 

  32. Grumbach MM and Auchus RJ (1999) Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84: 4677–4694

    CAS  PubMed  Google Scholar 

  33. Mittre Herve MH et al. (2004) Human gene mutations. Gene symbol: CYP19. Disease: aromatase deficiency. Hum Genet 114: 224

    CAS  PubMed  Google Scholar 

  34. Baumgartner RN et al. (1995) Human body composition and the epidemiology of chronic disease. Obes Res 3: 73–95

    Article  CAS  Google Scholar 

  35. Horber FF et al. (1997) Effect of sex and age on bone mass, body composition and fuel metabolism in humans. Nutrition 13: 524–534

    Article  CAS  Google Scholar 

  36. Isidori AM et al. (2005) Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 63: 381–394

    Article  CAS  Google Scholar 

  37. Reaven GM (2005) Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 1: 9–14

    Article  CAS  Google Scholar 

  38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497

  39. Prabhakaran D and Anand SS (2004) The metabolic syndrome: an emerging risk state for cardiovascular disease. Vasc Med 9: 55–68

    Article  Google Scholar 

  40. Carani C et al. (2005) Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism. Psychoneuroendocrinology 30: 413–417

    Article  CAS  Google Scholar 

  41. Carani C et al. (1999) Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 51: 517–524

    Article  CAS  Google Scholar 

  42. Harada N et al. (1992) Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem 267: 4781–4785

    CAS  PubMed  Google Scholar 

  43. Ito Y et al. (1993) Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA 90: 11673–11677

    Article  CAS  Google Scholar 

  44. World health Organization (1999) WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. Cambridge, UK: Cambridge University Press

  45. Esoterix Inc. Laboratory Services. Expected Values and S.I. Unit Conversion Pocket Book [http://www.esoterix.com/files/expected_values.pdf] (accessed 15 February 2006)

Download references

Acknowledgements

This work was supported by US Public Health Service Grant R37-AG08174, National Health and Medical Research Council (NHMRC) Project Grants 169010 and 338510, and NHMRC Fellowship Award 241024 to MEE Jones. Written consent for publication of the photograph used in Figure 1 was obtained from the patient and clinician involved.

Author information

Authors and Affiliations

  1. MEE Jones is a National Health and Medical Research (Australia) RD Wright Fellow and Senior Research Fellow, WC Boon is a Senior Research Officer, K McInnes is a Research Officer and ER Simpson is Professor, at Prince Henry's Institute of Medical Research, Melbourne, Victoria, Australia.,

    Margaret EE Jones, Wah Chin Boon, Kerry McInnes & Evan R Simpson

  2. L Maffei is the Medical Director of the Consultorios Asociados de Endocrinologia in Buenos Aires, Argentina.,

    Laura Maffei

  3. C Carani is Professor and Director of the Unit of Endocrinology in the University of Modena, Modena, Italy.,

    Cesare Carani

Authors
  1. Margaret EE Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wah Chin Boon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerry McInnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura Maffei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cesare Carani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Evan R Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret EE Jones.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, M., Boon, W., McInnes, K. et al. Recognizing rare disorders: aromatase deficiency. Nat Rev Endocrinol 3, 414–421 (2007). https://doi.org/10.1038/ncpendmet0477

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0477

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing